NCT05433935 Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
| NCT ID | NCT05433935 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang University |
| Condition | Intraductal Papillary Mucinous Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2032-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-07-01 with a primary completion date of 2032-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
Eligibility Criteria
Inclusion Criteria: * clinically diagnosed as IPMN; * without other malignant tumor; * agree to sign informed consent. Exclusion Criteria: * with mental disorders which can affect cognition and cooperation; * with serious blood diseases or taking drugs that can affect peripheral blood
Contact & Investigator
Tingbo Liang, PhD
STUDY CHAIR
Zhejiang University
Frequently Asked Questions
Who can join the NCT05433935 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 90 Years, studying Intraductal Papillary Mucinous Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05433935 currently recruiting?
Yes, NCT05433935 is actively recruiting participants. Contact the research team at liangtingbo@zju.edu.cn for enrollment information.
Where is the NCT05433935 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT05433935 clinical trial?
NCT05433935 is sponsored by Zhejiang University. The principal investigator is Tingbo Liang, PhD at Zhejiang University. The trial plans to enroll 5,000 participants.